Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101

Good tolerability allows for continued dose escalation in the dose-finding PANTAX phase 1b-trial with SCO-101 as combination therapy in pancreatic cancer. Consequently, readout from the trial is now expected in the first half of 2023.

The release as fetched from its publisher. scandiononcology.com ↗